PROALT participates in Anglonordic Life Science Conference 2022

Anti-CDH17 and anti-IL13Ra2 monoclonal antibodies developed by PROALT togheter with the Spanish Research Council (CSIC) are promising novel biological drugs to treat metastatic colorectal cancer (mCRC) and glioblastoma (GBM). Both could be new options for people whose cancers have not responded to previous lines of treatment. Delegates and Investors at the Anglonordic Life Science Conference [...]

2022-11-10T17:19:26+00:004 May 2022|Tags: |

ProAlt’s COO participates in a discussion panel at Asebio Investor Day 2022

PROTEIN ALTERNTIVES Chief Operating Officer Mr Juan Ignacio Imbaud has participated today in the second discussion panel "Boosting tech transfer in Biotechnology – turning ideas into technological solutions for society" at ASEBIO Investors Day organized by Asociación Española de Bioempresas. The panel was moderated by Carolina Pola, Innovation Strategist at Kaudal, and included reference speakers of the innovation ecosystem [...]

2022-11-10T16:38:18+00:0028 April 2022|Tags: |

PROALT awarded with the Prize for the BEST BIOTECHNOLOGICAL STARTUP

Protein Alternatives SL (PROALT) received the Prize as the BEST BIOTECHNOLOGICAL STARTUP in the first edition of the #startups #awards of LA RAZON. The event was chaired by the Mayor of Madrid José Luis Martínez-Almeida, who was accompanied by Andrés Navarro, CEO of LA RAZÓN and the director Francisco Marhuenda. This first edition of the Sartup Awards has [...]

2022-02-25T12:02:35+00:0024 February 2022|Tags: , , |

ProAlt will attended the 10th International Biotechnology Trade Show BioSpain 2021

September 14th, 2021 ProAlt will be present at BioSpain 2021 from the 29th September to the 1st October and will participate in the one-to-one meetings to present to investors and pharma companies the latest results of its anti-cadherins_RGD therapeutic antibodies in oncology. BioSpain is the 10th International Trade Show & Partnering Event that will take [...]

2021-09-14T13:52:12+00:0014 September 2021|Tags: , |

ProAlt at Swiss Biotech Day in Basel, Switzerland

September 07th, 2021 The Swiss Biotech Day is one of the leading biotechnology conferences in Europe coming back on stage on September 7, 2021 after the worldwide COVID-19 pandemic and will take place at Basel Congress Center. Today, PROALT will present to investors and pharma companies the recent advances with the therapeutic monoclonal antibody PA-0661 [...]

2021-09-14T13:17:13+00:007 September 2021|Tags: , |

ProAlt selected to participate in the EIC Corporate Day with Merck

September 6th, 2021 Protein Alternatives (ProAlt) was selected by the European Innovation Council Business Acceleration Services to present to Merck its therapeutic antibody PA-0661 in oncology. ProAlt will be one of the 16 selected companies from 10 different countries that will present innovative projects to Merck on September 30. Merck, the multinational Healthcare, Life Science [...]

2021-09-14T11:13:12+00:006 September 2021|Tags: , , , |

Protein Alternatives will participate in the XX Pharma-Biotech Cooperation Meeting organized by Farmaindustria

April 12th, 2021 The XX Pharma-Biotech Cooperation Meeting will be a digital event organized by FarmaIndustria in April 28, 2021 where selected projects from the Spanish National Research Council (CSIC) and its spin-offs will be presented to pharmaceutical companies. PROALT was selected to present its most advanced therapeutic product PA-0661, a monoclonal antibody for the [...]

2021-05-04T11:07:07+00:0012 April 2021|Tags: , |

Protein Alternatives receives the Innovative SME Seal

April 9th, 2021. PROALT has received the Innovative SME Seal, valid until April 2024. Innovation is one of the key factors for the economic and social development of any country. Through the Innovative SME Seal, the Ministry of Science and Innovation recognizes companies that carry out activities in the field of research, technological development and [...]

2021-05-04T11:07:52+00:009 April 2021|Tags: , , |

ProAlt’s MetasCure project selected in the R&D and innovation programme of Madrid Region

January 14th, 2021 Tres Cantos, Madrid, Spain. Protein Alternatives (PROALT), a leading company in the development of therapeutic monoclonal antibodies in oncology, has been selected as one of the two companies that will receive funding from the R&D and innovation programme of Madrid Region during 2021 and 2022. MetastCure project, with title “Preclinical evaluation of [...]

2021-05-04T11:08:46+00:0014 January 2021|Tags: , , , |

Protein Alternatives announces the opening of new office in Boston

December 1st, 2020 Tres Cantos, Madrid, Spain. Protein Alternatives (PROALT), a leading company in the development of diagnostic and therapeutic products in oncology and research services provider, announces today the opening of its new office in Boston at the Cambridge Innovation Center (CIC). United States is one of the priority markets for the organization and [...]

2020-12-01T11:29:02+00:001 December 2020|Tags: , |
Go to Top